Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer

In this secondary analysis of RTOG 9601, addition of anti-androgen therapy to radiotherapy following radical prostatectomy was associated with a survival benefit in those with PSA levels >1.5ng/mL (25% 12-year absolute benefit; HR 0.45; 95% 0.25-0.81) but not in PSA <1.5ng/mL.


JAMA Oncology